Limosilactobacillus reuteri ATCC PTA 4659

Based on the search results, I can provide the following information about Lactobacillus reuteri ATCC PTA 4659: Lactobacillus reuteri ATCC PTA 4659 (now known as Limosilactobacillus reuteri ATCC PTA 4659) is a probiotic strain with strong anti-inflammatory properties. This strain has been studied for its potential therapeutic benefits in various inflammatory conditions, particularly in gastrointestinal disorders. The strain has been shown to reduce inflammation in patients with diverticulitis and has demonstrated safety for human consumption[1][2]. Genomic analysis confirms its identity as Limosilactobacillus reuteri with no antibiotic resistance genes or virulence factors detected[2]. ## Therapeutic Applications Lactobacillus reuteri ATCC PTA 4659 has been investigated for several clinical applications: 1. **Acute Uncomplicated Diverticulitis**: A randomized double-blind placebo-controlled trial showed that supplementation with L. reuteri ATCC PTA 4659 significantly reduced abdominal pain and inflammatory markers in patients with acute uncomplicated diverticulitis[7]. 2. **Ulcerative Colitis**: Clinical trials have explored its potential to reduce relapse rates in ulcerative colitis patients[4][6]. The strain appears to play an essential role in anti-inflammatory effects by reducing the number of CD11b+CD11c+ dendritic cells and regulating the function of mesenteric lymph nodes[9]. 3. **Intestinal Inflammation**: Studies have shown that L. reuteri ATCC PTA 4659 can enhance the expression of heat shock proteins (HSP70 and HSP25) in the distal colon, which helps protect the gut epithelium against oxidative stress and inflammation[9]. ## Mechanism of Action The anti-inflammatory properties of L. reuteri ATCC PTA 4659 appear to work through several mechanisms: 1. It reduces bacterial translocation from the intestine to mesenteric lymph nodes, which may be an important part of how it ameliorates colitis[6]. 2. It differentially regulates LPS-induced chemokine profiles, downregulating the expression of several chemokines including Ccl2, Ccl12, Ccl19, Cx3Cr1, and IL8ra[8]. 3. It enhances the intestinal barrier by regulating the expression of tight junction proteins[9]. Clinical studies have confirmed that this strain survives passage through the human gastrointestinal tract, which is essential for its probiotic effects[5][10].

Other names

Lactobacillus reuteri ATCC PTA 4659